Placeholder Banner

Cartier Esham’s Testimony to Energy and Commerce Health Subcommittee on Treatments and Cures for Neurodegenerative Diseases

July 30, 2021

BIO regularly publishes reports that help us assess the health of the biopharmaceutical pipeline across different diseases so that we can identify and remove barriers to providing next generation cures and treatments to patients and their families. I will highlight three such analyses with a focus on neurology clinical development programs (pipeline, investment and clinical trial success rates) with the goal of providing helpful insights to this important conversation. Later I will do a deeper dive into Alzheimer’s Disease as an example of the state of innovation for neurodegenerative diseases.

Download Full Comments Below
Testimony to Energy and Commerce Health Subcommittee on Treatments and Cures for Neurodegenerative Diseases
Discover More
BIO is pleased to join the undersigned food and agriculture organizations and companies in supporting the nomination of Elaine Trevino to serve as Chief Agricultural Negotiator at the Office of the U.S. Trade Representative.
As you know, several challenges facing the agriculture industry and our communities have emerged or intensified in recent years. Zoonotic disease, climate change, and a growing global population require us to consider new solutions to protect our…
The Biotechnology Innovation Organization (BIO) submits these comments in response to the U.S. Environmental Protection Agency’s (EPA) request for public input on the receipt of an application, 93167-EUP-2, from Oxitec Ltd requesting to amend and…